Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101788 · ClinicalTrials.gov registry record · Phase 2
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT02101788: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02101788 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 260 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02101788, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Paclitaxel
- OTHER Questionnaire Administration
- DRUG Letrozole
- DRUG Pegylated Liposomal Doxorubicin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2014-04-11 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101788
The ClinicalTrials.gov registry entry for NCT02101788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02101788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02101788 about?
NCT02101788 is a clinical study titled "Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer". This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), b...
What is the current status of trial NCT02101788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2014-04-11. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT02101788?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Paclitaxel (DRUG), Questionnaire Administration (OTHER), Letrozole (DRUG), Pegylated Liposomal Doxorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02101788?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.